Intelligent Bio Solutions Inc. announced that it expects to receive its sixth patent in the United States, which will strengthen the protection of the lateral flow technology central to its Intelligent Fingerprinting Drug Testing Solution. This anticipated patent will enhance INBS’s existing intellectual property portfolio.
The expected grant will help ensure that the company’s lateral flow technology remains protected as it advances its U.S. market entry strategy. Protecting proprietary technology is critical as INBS plans to scale its footprint in the U.S. drug screening market.
This development strengthens INBS's competitive position ahead of its planned entry into the multi-billion dollar U.S. market in 2025. The company's technology provides a non-invasive alternative to traditional drug screening methods, meeting rising demand for workplace safety and compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.